<DOC>
	<DOC>NCT01350141</DOC>
	<brief_summary>PF-04950615 is a new investigational hypercholesterolemic agent that is being tested in this study to evaluate if it can lower LDL cholesterol.</brief_summary>
	<brief_title>A Multiple Dose Study Of PF-04950615 (RN316) In Subjects On Maximum Doses Of Statins</brief_title>
	<detailed_description />
	<mesh_term>Hypercholesterolemia</mesh_term>
	<mesh_term>Dyslipidemias</mesh_term>
	<criteria>Body Mass Index (BMI) of 18.5 to 40 kg/m2 On a stable maximum daily dose of a statin, defined as atorvastatin 80 mg or rosuvastatin 40 mg for a minimum of 45 days prior to Day 1. Lipids meet the following criteria twice during screening period: Fasting LDL C = or &gt; 80 mg/dL; Fasting TG &lt; 400 mg/dL. History of a cardiovascular or cerebrovascular event or procedure (eg, MI, stroke, TIA, angioplasty) during the past year. Poorly controlled type 1 or type 2 diabetes mellitus. Poorly controlled hypertension. Fasting triglycerides &gt; 400 mg/dL 12 lead ECG demonstrating QTcFF &gt;455 msec at screening.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2013</verification_date>
	<keyword>Hypercholesterolemia</keyword>
	<keyword>dyslipidemia</keyword>
	<keyword>high cholesterol</keyword>
	<keyword>LDL</keyword>
	<keyword>antibody</keyword>
	<keyword>PCSK9</keyword>
	<keyword>PF-04950615</keyword>
	<keyword>RN316</keyword>
</DOC>